272 related articles for article (PubMed ID: 26986757)
1. Amelioration of Diabetic Mouse Nephropathy by Catalpol Correlates with Down-Regulation of Grb10 Expression and Activation of Insulin-Like Growth Factor 1 / Insulin-Like Growth Factor 1 Receptor Signaling.
Yang S; Deng H; Zhang Q; Xie J; Zeng H; Jin X; Ling Z; Shan Q; Liu M; Ma Y; Tang J; Wei Q
PLoS One; 2016; 11(3):e0151857. PubMed ID: 26986757
[TBL] [Abstract][Full Text] [Related]
2. Effect of catalpol on diabetic nephropathy in rats.
Dong Z; Chen CX
Phytomedicine; 2013 Aug; 20(11):1023-9. PubMed ID: 23746755
[TBL] [Abstract][Full Text] [Related]
3. Insulin deficiency induces rat renal mesangial cell dysfunction via activation of IGF-1/IGF-1R pathway.
Kong YL; Shen Y; Ni J; Shao DC; Miao NJ; Xu JL; Zhou L; Xue H; Zhang W; Wang XX; Lu LM
Acta Pharmacol Sin; 2016 Feb; 37(2):217-27. PubMed ID: 26775660
[TBL] [Abstract][Full Text] [Related]
4. Growth factor receptor-bound protein 10-mediated negative regulation of the insulin-like growth factor-1 receptor-activated signalling pathway results in cognitive disorder in diabetic rats.
Ma L; Wei Q; Deng H; Zhang Q; Li G; Tang N; Xie J; Chen Y
J Neuroendocrinol; 2013 Jul; 25(7):626-34. PubMed ID: 23614367
[TBL] [Abstract][Full Text] [Related]
5. Global gene expression analysis in liver of db/db mice treated with catalpol.
Liu J; Zhang HR; Hou YB; Jing XL; Song XY; Shen XP
Chin J Nat Med; 2018 Aug; 16(8):590-598. PubMed ID: 30197124
[TBL] [Abstract][Full Text] [Related]
6. Study on the inhibitive effect of Catalpol on diabetic nephropathy.
Chen J; Yang Y; Lv Z; Shu A; Du Q; Wang W; Chen Y; Xu H
Life Sci; 2020 Sep; 257():118120. PubMed ID: 32693244
[TBL] [Abstract][Full Text] [Related]
7. IGF-1/IGF-1R blockade ameliorates diabetic kidney disease through normalizing Snail1 expression in a mouse model.
Dong R; Yu J; Yu F; Yang S; Qian Q; Zha Y
Am J Physiol Endocrinol Metab; 2019 Oct; 317(4):E686-E698. PubMed ID: 31361542
[TBL] [Abstract][Full Text] [Related]
8. Catalpol ameliorates hepatic insulin resistance in type 2 diabetes through acting on AMPK/NOX4/PI3K/AKT pathway.
Yan J; Wang C; Jin Y; Meng Q; Liu Q; Liu Z; Liu K; Sun H
Pharmacol Res; 2018 Apr; 130():466-480. PubMed ID: 29284152
[TBL] [Abstract][Full Text] [Related]
9. IGF-1R Inhibitor Ameliorates Diabetic Nephropathy with Suppressed HMGN1/TLR4 Pathway.
Yu J; Da J; Dong R; Sun Y; Nie Y; Yu F; Zuo L; Zha Y
Endocr Metab Immune Disord Drug Targets; 2018; 18(3):241-250. PubMed ID: 29384065
[TBL] [Abstract][Full Text] [Related]
10. Skimmin, a coumarin, suppresses the streptozotocin-induced diabetic nephropathy in wistar rats.
Zhang S; Yang J; Li H; Li Y; Liu Y; Zhang D; Zhang F; Zhou W; Chen X
Eur J Pharmacol; 2012 Oct; 692(1-3):78-83. PubMed ID: 22664227
[TBL] [Abstract][Full Text] [Related]
11. Regulation of insulin and type 1 insulin-like growth factor signaling and action by the Grb10/14 and SH2B1/B2 adaptor proteins.
Desbuquois B; Carré N; Burnol AF
FEBS J; 2013 Feb; 280(3):794-816. PubMed ID: 23190452
[TBL] [Abstract][Full Text] [Related]
12. Catalpol ameliorates endothelial dysfunction and inflammation in diabetic nephropathy via suppression of RAGE/RhoA/ROCK signaling pathway.
Shu A; Du Q; Chen J; Gao Y; Zhu Y; Lv G; Lu J; Chen Y; Xu H
Chem Biol Interact; 2021 Oct; 348():109625. PubMed ID: 34416245
[TBL] [Abstract][Full Text] [Related]
13. The adapter protein GRB10 is an endogenous negative regulator of insulin-like growth factor signaling.
Dufresne AM; Smith RJ
Endocrinology; 2005 Oct; 146(10):4399-409. PubMed ID: 16037382
[TBL] [Abstract][Full Text] [Related]
14. Growth receptor binding protein 10 inhibits glucose-stimulated insulin release from pancreatic β-cells associated with suppression of the insulin/insulin-like growth factor-1 signalling pathway.
Li L; Li X; Zhu Y; Zhang M; Yin D; Lu J; Liu F; Wang C; Jia W
Clin Exp Pharmacol Physiol; 2013 Dec; 40(12):841-7. PubMed ID: 23937793
[TBL] [Abstract][Full Text] [Related]
15. Autocrine activation of the local insulin-like growth factor I system is up-regulated by estrogen receptor (ER)-independent estrogen actions and accounts for decreased ER expression in type 2 diabetic mesangial cells.
Karl M; Potier M; Schulman IH; Rivera A; Werner H; Fornoni A; Elliot SJ
Endocrinology; 2005 Feb; 146(2):889-900. PubMed ID: 15550505
[TBL] [Abstract][Full Text] [Related]
16. Nedd4 controls animal growth by regulating IGF-1 signaling.
Cao XR; Lill NL; Boase N; Shi PP; Croucher DR; Shan H; Qu J; Sweezer EM; Place T; Kirby PA; Daly RJ; Kumar S; Yang B
Sci Signal; 2008 Sep; 1(38):ra5. PubMed ID: 18812566
[TBL] [Abstract][Full Text] [Related]
17. Meg1/Grb10 overexpression causes postnatal growth retardation and insulin resistance via negative modulation of the IGF1R and IR cascades.
Shiura H; Miyoshi N; Konishi A; Wakisaka-Saito N; Suzuki R; Muguruma K; Kohda T; Wakana S; Yokoyama M; Ishino F; Kaneko-Ishino T
Biochem Biophys Res Commun; 2005 Apr; 329(3):909-16. PubMed ID: 15752742
[TBL] [Abstract][Full Text] [Related]
18. Inhibitor of IGF1 receptor alleviates the inflammation process in the diabetic kidney mouse model without activating SOCS2.
Li J; Dong R; Yu J; Yi S; Da J; Yu F; Zha Y
Drug Des Devel Ther; 2018; 12():2887-2896. PubMed ID: 30254418
[TBL] [Abstract][Full Text] [Related]
19. Plasma glucose lowering mechanisms of catalpol, an active principle from roots of Rehmannia glutinosa, in streptozotocin-induced diabetic rats.
Shieh JP; Cheng KC; Chung HH; Kerh YF; Yeh CH; Cheng JT
J Agric Food Chem; 2011 Apr; 59(8):3747-53. PubMed ID: 21391677
[TBL] [Abstract][Full Text] [Related]
20. Catalpol suppresses advanced glycation end-products-induced inflammatory responses through inhibition of reactive oxygen species in human monocytic THP-1 cells.
Choi HJ; Jang HJ; Chung TW; Jeong SI; Cha J; Choi JY; Han CW; Jang YS; Joo M; Jeong HS; Ha KT
Fitoterapia; 2013 Apr; 86():19-28. PubMed ID: 23376161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
